Point72 reports shared beneficial ownership of Syndax Pharmaceuticals common stock. As of the close of business on March 31, 2026, Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen are reported to beneficially own 1,985,547 shares, representing 2.3% of the class. The filing states the reported position reflects shared voting and shared dispositive power of 1,985,547 shares and that the reporting persons own no shares directly.
The statement lists the filing entities and their roles: Point72 Asset Management (investment manager), Point72 Capital Advisors Inc. (general partner), and Mr. Cohen (controls both). The address for the reporting persons is provided as 72 Cummings Point Road, Stamford, CT 06902. The filing is an amendment to a Schedule 13G and reflects holdings reported for disclosure purposes.
Positive
None.
Negative
None.
Insights
Point72 reports a 2.3% passive stake via shared voting and dispositive power.
Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen are disclosed as reporting persons with 1,985,547 shares of Common Stock as of March 31, 2026. The cover rows in the filing show shared voting and shared dispositive power for the same share count.
The filing describes the governance relationship: Point72 Asset Management manages the fund holding the shares, Point72 Capital Advisors Inc. is the general partner, and Mr. Cohen controls both entities. Subsequent filings would show any changes in position or voting power.
Key Figures
Shares beneficially owned:1,985,547 sharesPercent of class:2.3%Securities class:Common Stock, par value $0.0001 per share
3 metrics
Shares beneficially owned1,985,547 sharesas of March 31, 2026
Percent of class2.3%as of March 31, 2026
Securities classCommon Stock, par value $0.0001 per shareCUSIP 87164F105
Key Terms
shared dispositive power, investment management agreement, Form ADV
3 terms
shared dispositive powerregulatory
"Shared Dispositive Power 1,985,547.00"
investment management agreementfinancial
"Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
Form ADVregulatory
"Each of Cubist Systematic Strategies, LLC, Point72 (DIFC) Limited, and Point72 Europe (London) LLP are relying advisers on the Form ADV"
Point72 reports beneficial ownership of 1,985,547 shares, representing 2.3% of Syndax Pharmaceuticals common stock as of March 31, 2026. The position is reported as shared voting and shared dispositive power held through managed funds.
Which entities filed the Schedule 13G/A for SNDX?
The filing is made by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen. Point72 Capital Advisors Inc. is the general partner and Point72 Asset Management is the investment manager for the fund holding the shares.
Does Point72 own the shares directly according to the filing?
No. The filing states the reporting persons own directly no shares; investment and voting power are held by Point72 Asset Management with respect to shares held by a fund it manages. Control relationships are disclosed in Item 4.
What voting and dispositive powers are reported?
The cover rows and Item 4 indicate 0 sole voting power and 1,985,547 shared voting power, and 0 sole dispositive power with 1,985,547 shared dispositive power, all as of March 31, 2026.
When was the Schedule 13G/A signed and filed?
The signatures in the amendment are dated May 15, 2026, and the ownership amounts reported are stated as of the close of business on March 31, 2026. The filing is labeled as Amendment No. 1.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Syndax Pharmaceuticals Inc
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
87164F105
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
87164F105
1
Names of Reporting Persons
Point72 Asset Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,985,547.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,985,547.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,985,547.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.3 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
87164F105
1
Names of Reporting Persons
Point72 Capital Advisors, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,985,547.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,985,547.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,985,547.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.3 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
87164F105
1
Names of Reporting Persons
Steven A. Cohen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,985,547.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,985,547.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,985,547.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.3 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Syndax Pharmaceuticals Inc
(b)
Address of issuer's principal executive offices:
730 Third Avenue, 9th Floor, New York, NY 10017
Item 2.
(a)
Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Shares"), of Syndax Pharmaceuticals Inc. held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the Shares held by an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
Each of Cubist Systematic Strategies, LLC, Point72 (DIFC) Limited, and Point72 Europe (London) LLP are relying advisers on the Form ADV of Point72 Asset Management and each acts as a sub-advisor with respect to a portion of the Shares reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
87164F105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein.
(b)
Percent of class:
2.3%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
